Vivatides Therapeutics Secures $54 Million Series A Financing to Advance Extrahepatic Targeted Oligonucleotide Therapies
Vivatides Therapeutics
Small Nucleic Acid Drug Developer
Recently,Vivatides Therapeutics Limited (referred to as "Vivatides Therapeutics"), an international innovative pharmaceutical company focusing on the development of small nucleic acid drugs targeting extrahepatic indications, announced the completion of a $54 million Series A financing round that was oversubscribed.This round of financing was jointly led by Qiming Venture Partners and a well-known industry fund, with active participation from Hony Capital, a well-known investment fund, and TF Capital. The existing investor, Apricot Capital, continued to increase its investment.
The funds from this round of financing will be mainly used for the iterative optimization of the company's core extrahepatic delivery technology platform, the clinical advancement of multiple pipelines, and the expansion of the team and the establishment of a global R&D network. As an emerging force in the small nucleic acid sector, Vivatides Therapeutics has successfully completed seed and Series A rounds of financing within less than a year of its establishment, demonstrating the investment market's high recognition of the company’s technological breakthrough capabilities and efficient execution in the extrahepatic small nucleic acid field.
Vivatides Therapeutics was founded in 2025 in Suzhou, Jiangsu, China, and has consistently focused on the independent innovation and transformation of extrahepatic small nucleic acid delivery technologies. The company's international core team is composed of senior experts from global leading small nucleic acid enterprises such as Arrowhead, Ionis, Alnylam, and Dicerna, who have led the development of multiple extrahepatic pipelines and platform construction. Members of the team have cumulatively led or been deeply involved in several extrahepatic small nucleic acid projects, many of which have entered the clinical development stage.
Relying on the technical accumulation of an international team, Vivatides Therapeutics has built a liver-excluded delivery platform with differentiated advantages, while also possessing core R&D capabilities in both siRNA and ASO. Key breakthroughs have been achieved in ligand conjugation, delivery efficiency, tissue targeting accuracy, and safety. Substantial progress has already been made in animal experiments. Combined with leading sequence design and target exploration capabilities, this has laid a solid foundation for the rapid advancement and expansion of multiple pipelines.
"Extrhepatic targeted delivery is the core key for small nucleic acid technology to move from 'rare diseases' to 'common chronic diseases.'"Dr. Keming Zhou, founder of Vivatides Therapeutics, stated:"We are honored to have received support and recognition from several top-tier investment institutions. This round of financing will accelerate the iteration of our technology platform and pipeline development, promoting the clinical translation of innovative small nucleic acid therapies in extrahepatic disease areas. We firmly believe that by overcoming delivery bottlenecks, small nucleic acid drugs will revolutionize treatment paradigms across a broader range of disease areas. We also look forward to further communication and collaboration with more long-term value-oriented partners, bringing new therapeutic options to patients worldwide."
Dr. Chen Kan, Partner of Qiming Venture Partners and Co-Head of the Healthcare Innovation Sector, stated:"We are optimistic about the long-term application potential of small nucleic acid drugs in a wider range of disease areas. Continuous advancements in extrahepatic targeting technology are constantly expanding their clinical boundaries. Vivatides Therapeutics has demonstrated solid technical expertise and efficient execution capabilities, with its platform already achieving positive progress. We look forward to the company continuing to drive technological breakthroughs, accelerating pipeline translation into clinical applications, and bringing safer and more effective innovative therapies to patients worldwide."
Dr. Wei Ding, partner of existing investor Apricot Capital, stated:"As the seed-round investor of Vivatides Therapeutics, we are delighted to witness the company’s efficient completion of Series A financing and warmly welcome the new investors. Since its establishment, we have been pleased to see that the team led by Dr. Zhou Keming has consistently exceeded expectations in platform iteration and pipeline advancement with extremely high execution efficiency. We look forward to Vivatides accelerating the transformation of its differentiated innovation platform into breakthrough therapies that benefit patients worldwide, continuing to lead the wave of research and development in liver-targeted nucleic acid drugs."
After this round of financing, Vivatides Therapeutics will further accelerate the optimization of its preclinical pipeline and the preparation for IND applications. At the same time, it will continue to expand its R&D and management teams and deepen the platform construction of extrahepatic delivery technologies. In the future, the company will focus on meeting unmet clinical needs, concentrating on high-incidence, high-demand extrahepatic disease areas. It aims to become a global leader in the development of extrahepatic small nucleic acid drugs, providing more efficient and safer innovative therapies for patients worldwide.
E.N.D
ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following information when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also indicate.
Statement:ReferenceInternalVolumeComeSource: Official Media/Online News, this publicPublic AccountAiming toKnowledge sharing, remaining neutral on the content, statements, and viewpoints of reprinted or shared materials, without guaranteeing their accuracy.Accuracy, reliability, or completeness, no express or implied warranty is made, and the relevant content is for reference only.